- Home
- ONDS vs VRDN Comparison
ONDS vs VRDN Comparison
Compare ONDS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- VRDN
- Stock Information
- Founded
- ONDS 2014
- VRDN 2006
- Country
- ONDS United States
- VRDN United States
- Employees
- ONDS N/A
- VRDN N/A
- Industry
- ONDS Telecommunications Equipment
- VRDN Medical Specialities
- Sector
- ONDS Telecommunications
- VRDN Health Care
- Exchange
- ONDS Nasdaq
- VRDN Nasdaq
- Market Cap
- ONDS 1.6B
- VRDN 1.5B
- IPO Year
- ONDS N/A
- VRDN N/A
- Fundamental
- Price
- ONDS $6.10
- VRDN $18.62
- Analyst Decision
- ONDS Strong Buy
- VRDN Strong Buy
- Analyst Count
- ONDS 3
- VRDN 11
- Target Price
- ONDS $5.67
- VRDN $38.80
- AVG Volume (30 Days)
- ONDS 47.6M
- VRDN 778.9K
- Earning Date
- ONDS 11-11-2025
- VRDN 11-11-2025
- Dividend Yield
- ONDS N/A
- VRDN N/A
- EPS Growth
- ONDS N/A
- VRDN N/A
- EPS
- ONDS N/A
- VRDN N/A
- Revenue
- ONDS $16,131,404.00
- VRDN $305,000.00
- Revenue This Year
- ONDS $246.94
- VRDN N/A
- Revenue Next Year
- ONDS $161.09
- VRDN $35,092.81
- P/E Ratio
- ONDS N/A
- VRDN N/A
- Revenue Growth
- ONDS 75.16
- VRDN 5.90
- 52 Week Low
- ONDS $0.57
- VRDN $9.90
- 52 Week High
- ONDS $6.86
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- ONDS 63.43
- VRDN 50.55
- Support Level
- ONDS $5.21
- VRDN $17.91
- Resistance Level
- ONDS $6.86
- VRDN $20.51
- Average True Range (ATR)
- ONDS 0.63
- VRDN 0.93
- MACD
- ONDS -0.02
- VRDN -0.15
- Stochastic Oscillator
- ONDS 61.22
- VRDN 27.31
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).